Form 4: CytoDyn CEO Granted 4.87M Stock Options

CytoDyn Inc.'s CEO, Jacob P. Lalezari, was granted 4,874,691 non-qualified stock options with an exercise price of $0.28, vesting over several years.

Summary

• Jacob P. Lalezari, Chief Executive Officer of CytoDyn Inc. (CYDY), was granted 4,874,691 non-qualified stock options.
• The options have an exercise price of $0.28 per share.
• The grant was approved by the Company's Compensation Committee on March 20, 2026, as an annual grant for fiscal year 2026.
• This award is consistent with past practice in recent years and utilizes shares reserved under the Issuer's 2012 Equity Incentive Plan, as amended.
• Vesting schedule: 1,218,672 shares will vest on March 20, 2027, with the remaining balance vesting in approximately equal monthly installments from April 2027 through March 2030.
• The options have an expiration date of March 20, 2036.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event. It's a routine executive compensation disclosure that aligns management incentives with shareholder interests, without introducing new fundamental information about the company's operations or financial health.

Positives

• The grant of stock options aligns the Chief Executive Officer's interests with those of shareholders, incentivizing long-term performance.
• The award is consistent with the company's established compensation practices and approved equity incentive plan.

Future Outlook

The vesting schedule indicates that a significant portion of the options will become exercisable over the next four years, providing a long-term incentive for the CEO.

Management Comments

• This grant was approved by the Company's Compensation Committee on March 20, 2026, and represents the annual grant to the individual for fiscal year 2026 consistent with past practice in recent years.
• This award was made in compliance with, and uses shares that are specifically reserved for issuance to employees, directors, and certain outside consultants under, the Issuer's 2012 Equity Incentive Plan, as amended.

Industry Context

StockSavvy.ai notes that the granting of stock options to executive leadership is a common practice across industries, particularly in biotechnology and growth-oriented companies, to align management incentives with long-term shareholder value creation.

Comparison to Industry Standards

• Executive equity compensation, such as stock option grants, is a standard component of remuneration packages for CEOs in publicly traded companies, especially within the biotech sector where long-term development cycles are prevalent.
• The multi-year vesting schedule is typical for such grants, designed to retain executives and incentivize sustained performance over several fiscal periods, comparable to practices at companies like Amgen or Gilead Sciences for their executive teams.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for future dilution upon exercise of options, but also increased alignment of CEO's long-term interests with shareholder value.
• Employees: The grant is part of a broader equity incentive plan that can also benefit other employees, fostering a performance-driven culture.

Next Steps

• The options will begin vesting on March 20, 2027, with subsequent monthly vesting through March 2030.
• The CEO may exercise these options at the specified price of $0.28 per share at any time after vesting and before the expiration date of March 20, 2036.

Key Dates

Recommendation

This Form 4 filing details a routine executive compensation event (an annual stock option grant) and does not contain new material information regarding the company's operational performance, financial outlook, or strategic direction that would warrant a change in investment recommendation. It primarily serves to align management incentives.

Keywords

CytoDyn, CYDY, stock option, executive compensation, Form 4, equity incentive plan, CEO